Last reviewed · How we verify
Vaxigrip tetra
Vaxigrip tetra is a Inactivated vaccine Biologic drug developed by The University of Hong Kong. It is currently in Phase 3 development for Prevention of seasonal influenza in individuals 6 months of age and older.
Vaxigrip tetra is a quadrivalent inactivated influenza vaccine.
Vaxigrip Tetra is a tetravalent influenza vaccine, which means it protects against four different strains of the influenza virus. It is classified as a small molecule, according to ChEMBL, and has been studied in clinical trials for its effectiveness against influenza and SARS-CoV-2 infections.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vaxigrip tetra |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
It contains inactivated viruses of four different influenza strains, which stimulate the body's immune system to produce antibodies against these strains. This provides immunity against seasonal influenza A and B viruses.
Approved indications
- Prevention of seasonal influenza in individuals 6 months of age and older
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE (PHASE4)
- INfluenza VaccInation To Mitigate typE 1 Diabetes (PHASE4)
- Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
- Maternal Determinants of Immunity to Influenza (PHASE4)
- Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (PHASE3)
- Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza (PHASE4)
- Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)
- Pregnancy, Arsenic and Immune Response
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaxigrip tetra CI brief — competitive landscape report
- Vaxigrip tetra updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI
Frequently asked questions about Vaxigrip tetra
What is Vaxigrip tetra?
How does Vaxigrip tetra work?
What is Vaxigrip tetra used for?
Who makes Vaxigrip tetra?
What drug class is Vaxigrip tetra in?
What development phase is Vaxigrip tetra in?
What are the side effects of Vaxigrip tetra?
Related
- Drug class: All Inactivated vaccine drugs
- Manufacturer: The University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Infectious disease
- Indication: Drugs for Prevention of seasonal influenza in individuals 6 months of age and older
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing